[A19-01] Nivolumab (melanoma) -Addendum to Commission A18-53

Last updated 21.03.2019

Project no.:

Commission awarded on 07.01.2019 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:


Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection

Result of dossier assessment:

Stage IIIB/C and IV disease: now hint of non-quantifiable added benefit. Stage IIIA disease: added benefit not proven


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Project no. Title Status
A18-53 Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V Commission completed

Federal Joint Committee (G-BA)

2019-02-21 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.